Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,281
  • Shares Outstanding, K 80,621
  • Annual Sales, $ 138,100 K
  • Annual Income, $ 31,870 K
  • EBIT $ 36 M
  • EBITDA $ 32 M
  • 60-Month Beta 2.05
  • Price/Sales 1.39
  • Price/Cash Flow 6.58
  • Price/Book 7.66

Options Overview Details

View History
  • Implied Volatility 151.17% ( +26.89%)
  • Historical Volatility 84.75%
  • IV Percentile 44%
  • IV Rank 25.37%
  • IV High 550.81% on 03/26/25
  • IV Low 15.34% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 34
  • Volume Avg (30-Day) 128
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 19,377
  • Open Int (30-Day) 19,609

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.05
  • Number of Estimates 4
  • High Estimate 0.02
  • Low Estimate -0.14
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +13.57%
on 06/25/25
2.79 -14.52%
on 07/10/25
+0.28 (+13.03%)
since 06/18/25
3-Month
0.63 +281.60%
on 04/30/25
3.10 -22.94%
on 06/13/25
+1.73 (+263.57%)
since 04/17/25
52-Week
0.40 +496.25%
on 04/07/25
3.10 -22.94%
on 06/13/25
+1.02 (+75.37%)
since 07/18/24

Most Recent Stories

More News
Emerging Oncology Breakthroughs Signal Opportunity Despite Research Funding Crunch

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Budget cuts are on the horizon for funding scientific research, and if supported by Congress, the development...

ONCY : 1.2700 (-3.79%)
CTMX : 2.38 (+0.21%)
NUVB : 2.30 (+2.68%)
IMRX : 4.13 (-3.95%)
ONC.TO : 1.73 (-2.81%)
CRDF : 4.28 (-3.82%)
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

CLDI : 0.5936 (-3.62%)
CRSP : 65.13 (+18.22%)
CTMX : 2.38 (+0.21%)
VRTX : 459.81 (-0.75%)
IBRX : 2.75 (-2.83%)
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

/CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is...

CLDI : 0.5936 (-3.62%)
CRSP : 65.13 (+18.22%)
CTMX : 2.38 (+0.21%)
VRTX : 459.81 (-0.75%)
IBRX : 2.75 (-2.83%)
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CTMX : 2.38 (+0.21%)
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

CTMX : 2.38 (+0.21%)
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

CTMX : 2.38 (+0.21%)
CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Therapeutics: Q1 Earnings Snapshot

CTMX : 2.38 (+0.21%)
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

CTMX : 2.38 (+0.21%)
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

CTMX : 2.38 (+0.21%)
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

CTMX : 2.38 (+0.21%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 2.58
2nd Resistance Point 2.54
1st Resistance Point 2.46
Last Price 2.38
1st Support Level 2.34
2nd Support Level 2.30
3rd Support Level 2.22

See More

52-Week High 3.10
Last Price 2.38
Fibonacci 61.8% 2.07
Fibonacci 50% 1.75
Fibonacci 38.2% 1.43
52-Week Low 0.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar